The reason why I think the start of Phase 2a trial for ATL1103 will be a hugh leap in SP is that Pfizer took over Excalliard at the end of their Phase 2 trial of EXC001.
However, soon after the take over, it actually started a separate Phase 2a trial on scar tissue for breasts augmentation. The commercialisation area of Pfizer could well be different from what the R&D company may concentrate on.
ATL1103 could be applicable to other areas that some big Pharma could be looking into that fits their current inhouse program other than Acromegaly.
The reason why I think the start of Phase 2a trial for ATL1103...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |